Cargando…
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrop...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348940/ https://www.ncbi.nlm.nih.gov/pubmed/32560364 http://dx.doi.org/10.3390/ijms21124312 |
_version_ | 1783556948166180864 |
---|---|
author | Bross, Madeline Hackett, Melody Bernitsas, Evanthia |
author_facet | Bross, Madeline Hackett, Melody Bernitsas, Evanthia |
author_sort | Bross, Madeline |
collection | PubMed |
description | Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrophy, or brain volume loss (BVL), as well as lesions, “black holes” and spinal cord atrophy. MRI outcomes such as BVL have been used as biomarkers of neurodegeneration and other measures of MS disease progression in clinical research settings. Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration, but there are still many shortcomings that current clinical research aims to mitigate. This review attempts to provide an overview of the FDA-approved medications available for treating multiple sclerosis and their effect on neurodegeneration, measured by BVL. |
format | Online Article Text |
id | pubmed-7348940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73489402020-07-15 Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis Bross, Madeline Hackett, Melody Bernitsas, Evanthia Int J Mol Sci Review Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrophy, or brain volume loss (BVL), as well as lesions, “black holes” and spinal cord atrophy. MRI outcomes such as BVL have been used as biomarkers of neurodegeneration and other measures of MS disease progression in clinical research settings. Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration, but there are still many shortcomings that current clinical research aims to mitigate. This review attempts to provide an overview of the FDA-approved medications available for treating multiple sclerosis and their effect on neurodegeneration, measured by BVL. MDPI 2020-06-17 /pmc/articles/PMC7348940/ /pubmed/32560364 http://dx.doi.org/10.3390/ijms21124312 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bross, Madeline Hackett, Melody Bernitsas, Evanthia Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title | Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title_full | Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title_fullStr | Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title_full_unstemmed | Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title_short | Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis |
title_sort | approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348940/ https://www.ncbi.nlm.nih.gov/pubmed/32560364 http://dx.doi.org/10.3390/ijms21124312 |
work_keys_str_mv | AT brossmadeline approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis AT hackettmelody approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis AT bernitsasevanthia approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis |